A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads

Inclusion Criteria: * Female age 21 years or older at the time of signing informed consent. * Documented pathologic diagnosis of invasive breast or gynecologic cancer, any stage, requiring treatment with a taxane-containing chemotherapy regimen * Planned start of treatment with taxane-based chemotherapy in the adjuvant, neoadjuvant or advanced setting * Plan to complete chemotherapy within 6 months of treatment start * If received prior chemotherapy causing hair loss, \>/= 2 years since last chemotherapy dose and complete recovery of hair * ECOG performance status 0-1 * Willing and able to sign informed consent for study procedures * Willing and able to participate in all study procedures Exclusion Criteria: * Plan to use chemotherapy regimen other than that listed in inclusion criteria, including any anthracycline-based regimen * Plan to initiate bone marrow ablation chemotherapy * History of or plan to initiate whole or partial brain or skull irradiation * Hormone therapy concurrent with current chemotherapy regimen * Existing or suspected scalp metastases * History of concomitant diagnosis of: autoimmune disease affecting hair; cryoglobulinemia; untreated iron deficiency with or without anemia; cold agglutination disease; post-traumatic cold dystrophy; untreated or poorly controlled hyper- or hypothyroidism * Female pattern baldness * History of persistent chemotherapy-induced alopecia from prior chemotherapy * Concomitant exposure to investigational agents, drugs, devices or procedures that cause hair loss * Concomitant other solid tumor or hematologic malignancy in addition to the current diagnosis